(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-1.04%) $82.98
(-1.16%) $1.619
(-0.44%) $2 336.80
(-0.49%) $27.40
(0.33%) $925.10
(-0.11%) $0.934
(-0.07%) $11.02
(-0.18%) $0.799
(0.00%) $92.17
Live Chart Being Loaded With Signals
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders...
Stats | |
---|---|
Šios dienos apimtis | 261 676 |
Vidutinė apimtis | 261 312 |
Rinkos kapitalizacija | 66.40M |
EPS | $-0.290 ( 2024-04-02 ) |
Kita pelno data | ( $-0.280 ) 2024-05-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.230 |
ATR14 | $0.00500 (0.37%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-06 | Sandercock Colin | Buy | 175 000 | Stock Option (right to buy) |
2024-03-06 | Suri Anish | Buy | 300 000 | Stock Option (right to buy) |
2024-03-06 | Millar Kerri-ann | Buy | 250 000 | Stock Option (right to buy) |
2024-03-06 | Passeri Daniel R | Buy | 400 000 | Stock Option (right to buy) |
2024-03-06 | Levisetti Matteo | Buy | 260 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
98.01 |
Last 98 transactions |
Buy: 5 498 246 | Sell: 593 660 |
Tūris Koreliacija
Cue Biopharma Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
NLTX | 0.886 |
RPHM | 0.872 |
RNAZ | 0.843 |
SGTX | 0.843 |
ACLX | 0.842 |
ADMP | 0.842 |
NISN | 0.834 |
SDIG | 0.833 |
RMRM | 0.832 |
VCXA | 0.828 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
TCBS | -0.877 |
CDW | -0.875 |
MYNZ | -0.87 |
RGP | -0.865 |
RBBN | -0.863 |
PTSI | -0.862 |
CASS | -0.858 |
HOFT | -0.858 |
LSAK | -0.846 |
FFBW | -0.844 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Cue Biopharma Inc Koreliacija - Valiuta/Žaliavos
Cue Biopharma Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $5.49M |
Bruto pelnas: | $2.05M (37.41 %) |
EPS: | $-1.110 |
FY | 2023 |
Pajamos: | $5.49M |
Bruto pelnas: | $2.05M (37.41 %) |
EPS: | $-1.110 |
FY | 2022 |
Pajamos: | $1.25M |
Bruto pelnas: | $-560 828 (-45.04 %) |
EPS: | $-1.480 |
FY | 2021 |
Pajamos: | $14.94M |
Bruto pelnas: | $14.94M (100.00 %) |
EPS: | $-1.410 |
Financial Reports:
No articles found.
Cue Biopharma Inc
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.